Dasatinib resistant and sensitive prostatic cancer cell lines
Summary:
Analysis of 16 prostatic cancer cell lines treated with anti-tumor agent dasatinib. The cell lines display sensitivity or resistance to dasatinib. Results used to define a gene expression profile associated with sensitivity to dasatinib.
GPL571:
[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array
Citation:
Wang XD, Reeves K, Luo FR, Xu LA et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007;8(11):R255. PMID: 18047674
